The advent of immunotherapy against ccRCC, such as the targeting of PD-1, PD-L1, and CTLA4, has recently been demonstrated to revolutionize the clinical treatment for ccRCC (Farkona et al., 2016). Here, CD274 is linked to nonpapillary renal cell carcinoma.